Medscape is available in 5 Language Editions – Choose your Edition here.


Wernicke-Korsakoff Syndrome

  • Author: Glen L Xiong, MD; Chief Editor: David Bienenfeld, MD  more...
Updated: Apr 18, 2016


Wernicke-Korsakoff Syndrome (WKS) classically, but not always, presents with the clinical triad of confusion, ataxia, and nystagmus. It is best conceptualized as 2 distinct syndromes, with one being characterized by an acute/subacute confusional state and often reversible findings of Wernicke encephalopathy (a type of delirium) and the other by persistent and irreversible findings of Korsakoff dementia. (See Clinical and Workup.)

In 1881, Carl Wernicke first described an illness that consisted of paralysis of eye movements, ataxia, and mental confusion, in 3 patients. The patients, 2 males with alcoholism and a female with persistent vomiting following sulfuric acid ingestion, exhibited these findings, developed coma, and eventually died. On autopsy, Wernicke detected punctate hemorrhages affecting the gray matter around the third and fourth ventricles and aqueduct of Sylvius. He felt these to be inflammatory and therefore named the disease polioencephalitis hemorrhagica superioris.

Sergei Korsakoff, a Russian psychiatrist, described the disturbance of memory in the course of long-term alcoholism in a series of articles from 1887-1891. He termed this syndrome psychosis polyneuritica, believing that these typical memory deficits, in conjunction with polyneuropathy, represented different facets of the same disease. In 1897, Murawieff first postulated that a single etiology was responsible for both syndromes. (See Etiology.)



A deficiency of thiamine (vitamin B-1) is responsible for the symptom complex manifested in Wernicke-Korsakoff syndrome, and any condition resulting in a poor nutritional state places patients at risk. The structural lesions associated with Wernicke-Korsakoff syndrome are more likely to manifest in patients with malnutrition.[1] However, it is crucial to recognize that Wernicke-Korsakoff syndrome also appears in patients without exposure to alcohol. The occurrence of WKS in patients without alcohol use disorders is well described in the literature and cited in the section below.{ref53]

The following are associated with Wernicke-Korsakoff syndrome:

  • Chronic alcoholism - There may be a synergistically destructive effect of alcohol and thiamine deficiency that contributes to the Wernicke-Korsakoff syndrome. Alcohol interferes with active gastrointestinal transport, and chronic liver disease leads to decreased activation of thiamine pyrophosphate from thiamine, as well as decreased capacity of the liver to store thiamine. [2, 3, 4]
  • Bariatric surgery - Wernicke encephalopathy can present as early as 2 weeks after surgery; recovery typically occurs within 3-6 months of initiation of therapy but may be incomplete if this syndrome is not recognized promptly and treated (the highest risk is in young women with vomiting) [5, 6]
  • Nutritional deficiency and certain diets [7]
  • Starvation - Persons with anorexia nervosa, [8] schizophrenia, [9] or terminal cancer [10] ; prisoners of war
  • Thiamine-deficient formula [11]
  • Hyperemesis gravidarum - In a study of 49 cases of Wernicke encephalopathy in pregnancy, pregnancy loss attributable to Wernicke encephalopathy was nearly 48% [12]
  • Gastric malignancy, [13, 14] inflammatory bowel disease [15]
  • Intestinal obstruction, including abdominal abscess [16]
  • Plastic surgery - Panniculectomy [17]
  • Systemic diseases - Malignancy, [18, 19] disseminated tuberculosis, acquired immunodeficiency syndrome (AIDS), [20] uremia, stem cell transplantation [21]
  • Iatrogenic - Intravenous hyperalimentation (without thiamine supplementation), refeeding after starvation, chronic hemodialysis [22]
  • Encephalitic infections or infarctions affecting the mammillary bodies or hippocampus Rare reports - Rare reports [23]
  • Infants breastfed by mothers with inadequate intake of thiamine [24]


Thiamine is absorbed from the duodenum. The body has approximately 18 days of thiamine stores. Thiamine is converted to its active form, thiamine pyrophosphate, in neuronal and glial cells. Thiamine pyrophosphate serves as a cofactor for several enzymes, including transketolase, pyruvate dehydrogenase, and alpha ketoglutarate, that function in glucose use. The main function of these enzymes in the brain is lipid (myelin sheath) and carbohydrate metabolism, production of amino acids, and production of glucose-derived neurotransmitters.

Thiamine appears to have a role in axonal conduction, particularly in acetylcholinergic and serotoninergic neurons. A reduction in the function of these enzymes leads to diffuse impairment in the metabolism of glucose in key regions of the brain, resulting in impaired cellular energy metabolism.

Within 2-3 weeks of decreased intake and thiamine depletion, areas of the brain with the highest thiamine content and turnover demonstrate cellular impairment and injury. The earliest biochemical change is the decrease in α-ketoglutarate-dehydrogenase activity in astrocytes. Acute thiamine deficiency leads to mitochondrial dysfunction and therefore oxidative toxicity in areas of the brain starting with areas with the highest metabolic activity. The exact mechanism of neuronal cell death remains to be elucidated.[25]

Additional findings include increased astrocyte lactate and edema, increased extracellular glutamate concentrations, increased nitric oxide from endothelial cell dysfunction, deoxyribonucleic acid (DNA) fragmentation in neurons, free radical production and increase in cytokines, and breakdown of the blood-brain barrier. Thiamine appears to have a role in acetylcholinergic and serotoninergic synaptic transmission and axonal conduction.

Symptoms of Wernicke-Korsakoff syndrome are attributed to these focal areas of damage. Ocular motor signs are attributable to lesions in the brainstem affecting the abducens nuclei and eye movement centers in the pons and midbrain. These lesions are characterized by a lack of significant destruction to nerve cells, which accounts for the rapid improvement and degree of recovery observed with thiamine repletion.

Ataxia is a manifestation of damage to the cerebellum, particularly the superior vermis. The cerebellar changes consist of a degeneration of all layers of the cortex, particularly the Purkinje cells. The loss of neurons leads to persistent ataxia of gait and stance. In addition to cerebellar dysfunction, the vestibular apparatus is also affected. In addition, chronic alcohol consumption results in a 35% decrease in transketolase activity within the cerebellum, which is likely due to thiamine deficiency.

Vestibular paresis, confirmed by abnormal results on caloric testing, is observed in the early stages of disease and generally improves with treatment. The amnestic component is related to damage in the diencephalon, including the medial thalamus, and connections with the medial temporal lobes and amygdala. The slow and incomplete recovery of memory deficits suggests that amnesia is related to irreversible structural damage.

McEntee and colleagues demonstrated decreased levels of a metabolite of norepinephrine (3-methoxy-4-hydroxyphenolglycol, or MHPG) in the cerebrospinal fluid (CSF) of some patients with Wernicke-Korsakoff syndrome.[26] They pointed out that the diencephalic lesions are located within monoamine-containing pathways. Clonidine, an alpha-noradrenergic agonist, seemed to improve the memory disorder of their patients. They postulated that damage to these pathways may be the basis for the amnestic features of Wernicke-Korsakoff syndrome. These results have not been reproduced in any large prospective study. Patients with permanent Korsakoff psychosis are not routinely treated with clonidine.

Variants in the gene coding for the high-affinity thiamine transporter protein SLC19A2 in neurons may also contribute to the susceptibility of Wernicke-Korsakoff syndrome. Patients with a functional impairment in the ability to effectively transport thiamine may have impaired ability to cope with thiamine deficiency or respond to thiamine replacement.



Eighty-five percent of the survivors of the acute phase of Wernicke encephalopathy who remain untreated go on to develop Wernicke-Korsakoff syndrome.[27]

Occurrence in the United States

Long-standing alcohol use is the most common association with development of Wernicke-Korsakoff syndrome, although poor nutrition can also be an important factor. Prevalence data have come primarily from necropsy studies, with rates of 1-3%, and have indicated that prevalence at autopsy exceeds clinical detection. The rate has been found to be significantly higher in specific populations, ie, homeless people, older people (especially those living alone or in isolation), and psychiatric inpatients, where alcohol use and poor nutritional states predominate.

International occurrence

International and US rates of occurrence are essentially the same. In a survey of neuropathologists from several countries (Australia, Austria, Belgium, Czechoslovakia, France, Germany, Norway, United Kingdom, United States), prevalence ranged from 0-2.8%. Prevalence did not correlate with per capita alcohol consumption in each country.[28] In one study of 131 patients with post-mortem findings Wernicke’s encephalopathy, only 20% of the patients had a recorded diagnosis of the nutritional disorder.[29]

Sex-, age-, and race-related demographics

The condition affects males slightly more frequently than it affects females. Age of onset is evenly distributed from 30-70 years.

Studies have reported Wernicke encephalopathy in the pediatric population, often in association with malignancy. However, because of the prevalent role of alcohol in Wernicke-Korsakoff syndrome, it is very rarely reported in children. One report describes Wernicke-Korsakoff–like syndrome in a 10-year-old child who contracted herpesvirus encephalitis through an unrelated cord blood transplantation. The symptoms resolved with treatment of the virus, implying it had attacked the mammillothalamic system.[30]

While many clinicians empirically assume that age and the length of alcohol abuse are correlative with the risk of developing Wernicke-Korsakoff syndrome, there does not appear to be any controlled study evaluating this. Although studies have compared memory deficits in patients with Alzheimer dementia and Korsakoff syndrome (see the work of Michael D. Kopelman from the 1980s and 1990s), there do not appear to be studies looking at the impact of age-related atrophy or comorbid Alzheimer dementia as risk factors for Wernicke-Korsakoff syndrome.

The epidemiology of Wernicke-Korsakoff syndrome generally follows rates of alcoholism. There do not appear to be studies investigating or suggesting a genetic susceptibility of one racial group or sexual predisposition.



As many as 25% of patients with Wernicke-Korsakoff syndrome require long-term supervised care or institutionalization.[31] Patients depending on long-term care usually have comorbidity in more than one domain (somatic and psychiatric).[32]

Ocular complications

Patients who recover generally do so in a particular sequence. Improvement of ocular abnormalities is the earliest and most dramatic, usually occurring within hours of the initial thiamine dose. Failure of ocular abnormalities to respond to thiamine in this manner should raise doubt as to the veracity of the diagnosis.

Vertical nystagmus may persist for months. Fine horizontal nystagmus may persist indefinitely in as many as 60% of patients, but patients completely recover from sixth nerve palsies, ptosis, and vertical-gaze palsies.

Ataxic complications

Approximately 40% of patients recover completely from their ataxic symptoms. The remainder have varying degrees of incomplete recovery, with a residual slow, shuffling, wide-based gait and the inability to tandem walk. Vestibular dysfunction generally responds to a similar degree.

Mental status complications

The symptoms of global confusional state often resolve gradually after treatment is initiated. If an amnestic deficit is present, it will manifest as the early signs of apathy and global confusion resolve. Only 20% of patients who demonstrate signs of the amnestic state after treatment has been initiated have complete recovery. The remaining patients have varying degrees of persistent learning and memory impairment.

Maximum recovery may take 1 or more years and depends on abstinence from alcohol. According to reports, once patients with Korsakoff psychosis have recovered, they do not demand alcohol, but they will accept it if offered.


Mortality may be secondary to infections and hepatic failure, but some deaths are directly attributable to irreversible defects of severe and prolonged thiamine deficiency (eg, coma).

The mortality rate is up to 10-15% in severe cases. Since the presentation is variable and often clinically missed, the exact mortality rate is difficult to estimate. Prognosis depends on the stage of disease at presentation and prompt treatment. Unspecified infections were the cause of death in 77% of one cohort of Wernicke-Korsakoff patients.[33]


Patient Education

In alcohol-related Wernicke-Korsakoff syndrome, abstinence from alcohol and maintenance of a balanced diet offer the best chance for recovery and prevention of future episodes.

Patients who have undergone gastric bypass surgery are recommended to adhere to a balanced diet and continue vitamin supplementation.

Family education and support is an important component of taking care of anyone with a dementia illness, including Wernicke-Korsakoff syndrome. Patients with persistent dementia usually require 24-hour supervision, because they usually have poor insight into their illness and significant functional impairments in activities of daily living. Some patients with alcohol dependence may continue to prefer alcohol use, despite their cognitive deficits. In severe cases, private or public guardianships (or conservatorships) may need to be sought from the courts.

Some helpful Web sites for patients include the following:

Contributor Information and Disclosures

Glen L Xiong, MD Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, Department of Internal Medicine, University of California, Davis, School of Medicine; Medical Director, Sacramento County Mental Health Treatment Center

Glen L Xiong, MD is a member of the following medical societies: AMDA - The Society for Post-Acute and Long-Term Care Medicine, American College of Physicians, American Psychiatric Association, Central California Psychiatric Society

Disclosure: Received royalty from Lippincott Williams & Wilkins for book editor; Received grant/research funds from National Alliance for Research in Schizophrenia and Depression for independent contractor; Received consulting fee from Blue Cross Blue Shield Association for consulting. for: Received book royalty from American Psychiatric Publishing Inc.


Christopher A Kenedi, MD, MPH, FACP, FRACP Honorary Senior Lecturer, Auckland University School of Medicine; Consultant Physician and Psychiatrist, Liaison Psychiatry Division, Auckland City Hospital, New Zealand; Adjunct Faculty of Medicine, Adjunct Faculty of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina

Christopher A Kenedi, MD, MPH, FACP, FRACP is a member of the following medical societies: Academy of Psychosomatic Medicine, American College of Physicians, American Psychiatric Association, American Academy of HIV Medicine, Royal Australian and New Zealand College of Psychiatrists

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

David Bienenfeld, MD Professor, Departments of Psychiatry and Geriatric Medicine, Wright State University, Boonshoft School of Medicine

David Bienenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, Association for Academic Psychiatry

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Alan DeAngelo, MD; Alan Halliday, MD; and G Patrick Daubert, MD, to the development and writing of the source article.

  1. Thomson AD, Cook CC, Guerrini I, Sheedy D, Harper C, Marshall EJ. Wernicke's encephalopathy: 'Plus ça change, plus c'est la même chose'. Alcohol Alcohol. 2008 Mar-Apr. 43(2):180-6. [Medline].

  2. Thomson AD, Marshall EJ. The natural history and pathophysiology of Wernicke's Encephalopathy and Korsakoff's Psychosis. Alcohol Alcohol. 2006 Mar-Apr. 41(2):151-8. [Medline].

  3. Wijnia JW, van de Wetering BJ, Zwart E, Nieuwenhuis KG, Goossensen MA. Evolution of Wernicke-Korsakoff syndrome in self-neglecting alcoholics: preliminary results of relation with Wernicke-delirium and diabetes mellitus. Am J Addict. 2012 Mar-Apr. 21(2):104-10. [Medline].

  4. Thomson AD, Marshall EJ, Bell D. Time to act on the inadequate management of Wernicke's encephalopathy in the UK. Alcohol Alcohol. 2013 Jan-Feb. 48(1):4-8. [Medline].

  5. Singh S, Kumar A. Wernicke encephalopathy after obesity surgery: a systematic review. Neurology. 2007 Mar 13. 68(11):807-11. [Medline].

  6. Van Stavern G, Kumar G, Thuruthumaly C. Visual disturbance after bariatric surgery. JAMA Ophthalmol. 2015 Mar. 133 (3):345-6. [Medline].

  7. Hutcheon DA. Malnutrition-induced Wernicke's encephalopathy following a water-only fasting diet. Nutr Clin Pract. 2015 Feb. 30 (1):92-9. [Medline].

  8. Saad L, Silva LF, Banzato CE, Dantas CR, Garcia C Jr. Anorexia nervosa and Wernicke-Korsakoff syndrome: a case report. J Med Case Rep. 2010 Jul 20. 4:217. [Medline]. [Full Text].

  9. Harrison RA, Vu T, Hunter AJ. Wernicke's encephalopathy in a patient with schizophrenia. J Gen Intern Med. 2006 Dec. 21(12):C8-C11. [Medline]. [Full Text].

  10. Yae S, Okuno S, Onishi H, Kawanishi C. Development of Wernicke encephalopathy in a terminally ill cancer patient consuming an adequate diet: a case report and review of the literature. Palliat Support Care. 2005 Dec. 3(4):333-5. [Medline].

  11. Kesler A, Stolovitch C, Hoffmann C, Avni I, Morad Y. Acute ophthalmoplegia and nystagmus in infants fed a thiamine-deficient formula: an epidemic of Wernicke encephalopathy. J Neuroophthalmol. 2005 Sep. 25(3):169-72. [Medline].

  12. Chiossi G, Neri I, Cavazzuti M, Basso G, Facchinetti F. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet Gynecol Surv. 2006 Apr. 61(4):255-68. [Medline].

  13. Restivo A, Carta MG, Farci AM, Saiu L, Gessa GL, Agabio R. Risk of thiamine deficiency and Wernicke's encephalopathy after gastrointestinal surgery for cancer. Support Care Cancer. 2015 May 2. [Medline].

  14. Rakici SY, Erdemli SD, Yazici ZA, Cengiz E, Acar OG, Tufan G. Wernicke's encephalopathy in a patient with unresectable gastric carcinoma and literature review. Int J Clin Exp Med. 2015. 8 (1):1453-9. [Medline].

  15. Welsh A, Rogers P, Clift F. Nonalcoholic Wernicke's encephalopathy. CJEM. 2015 May 19. 1-4. [Medline].

  16. Schattner A, Kedar A. An unlikely culprit--the many guises of thiamine deficiency. Am J Emerg Med. 2013 Mar. 31(3):635.e5-6. [Medline].

  17. Gardiner S, Hartzell T. Thiamine Deficiency: A Cause of Profound Hypotension and Hypothermia After Plastic Surgery. Aesthet Surg J. 2014 Aug 13. [Medline].

  18. Han JW, Lim S, Shin HS, Park HJ, Jung WJ, Kwon SY, et al. Two cases of Wernicke's encephalopathy in young age patients receiving allogeneic hematopoietic stem cell transplantation. Yonsei Med J. 2012 Sep. 53(5):1049-53. [Medline]. [Full Text].

  19. Cefalo MG, De Ioris MA, Cacchione A, Longo D, Staccioli S, Arcioni F, et al. Wernicke Encephalopathy in Pediatric Neuro-oncology: Presentation of 2 Cases and Review of Literature. J Child Neurol. 2014 Dec. 29(12):NP181-5. [Medline].

  20. Alcaide ML, Jayaweera D, Espinoza L, Kolber M. Wernicke's encephalopathy in AIDS: a preventable cause of fatal neurological deficit. Int J STD AIDS. 2003 Oct. 14(10):712-3. [Medline].

  21. Steinberg A, Gorman E, Tannenbaum J. Thiamine deficiency in stem cell transplant patients: a case series with an accompanying review of the literature. Clin Lymphoma Myeloma Leuk. 2014 Sep. 14 Suppl:S111-3. [Medline].

  22. Ueda K, Takada D, Mii A, et al. Severe thiamine deficiency resulted in Wernicke's encephalopathy in a chronic dialysis patient. Clin Exp Nephrol. 2006 Dec. 10(4):290-3. [Medline].

  23. Rahme R, Moussa R, Awada A, et al. Acute Korsakoff-like amnestic syndrome resulting from left thalamic infarction following a right hippocampal hemorrhage. AJNR Am J Neuroradiol. 2007 Apr. 28(4):759-60. [Medline].

  24. Barennes H, Sengkhamyong K, René JP, Phimmasane M. Beriberi (thiamine deficiency) and high infant mortality in northern Laos. PLoS Negl Trop Dis. 2015 Mar. 9 (3):e0003581. [Medline].

  25. Abdou E, Hazell AS. Thiamine Deficiency: An Update of Pathophysiologic Mechanisms and Future Therapeutic Considerations. Neurochem Res. 2014 Oct 9. [Medline].

  26. McEntee WJ, Mair RG. Memory enhancement in Korsakoff's psychosis by clonidine: further evidence for a noradrenergic deficit. Ann Neurol. 1980 May. 7(5):466-70. [Medline].

  27. Day E, Bentham P, Callaghan R, Kuruvilla T, George S. Thiamine for Wernicke-Korsakoff Syndrome in people at risk from alcohol abuse. Cochrane Database Syst Rev. 2004. CD004033. [Medline].

  28. Harper C, Fornes P, Duyckaerts C, Lecomte D, Hauw JJ. An international perspective on the prevalence of the Wernicke-Korsakoff syndrome. Metab Brain Dis. 1995 Mar. 10(1):17-24. [Medline].

  29. Harper C. The incidence of Wernicke's encephalopathy in Australia--a neuropathological study of 131 cases. J Neurol Neurosurg Psychiatry. 1983 Jul. 46(7):593-8. [Medline]. [Full Text].

  30. Carvajal E, Verdeguer A, Fernández JM, Cañete A, Castel V. Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation. J Pediatr Hematol Oncol. 2001 Dec. 23(9):626-8. [Medline].

  31. Victor M, Adams RD, Collins GH. The Wernicke-Korsakoff syndrome. A clinical and pathological study of 245 patients, 82 with post-mortem examinations. Contemp Neurol Ser. 1971. 7:1-206. [Medline].

  32. Gerridzen IJ, Goossensen MA. Patients with Korsakoff syndrome in nursing homes: characteristics, comorbidity, and use of psychotropic drugs. Int Psychogeriatr. 2014 Jan. 26(1):115-21. [Medline].

  33. Victor M, Adams R, Collins G, eds. The Wernicke-Korsakoff syndrome and related neurologic disorders due to alcoholism and malnutrition. Philadelphia, Pa: FA Davis; 1989. 142-5.

  34. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007 May. 6(5):442-55. [Medline].

  35. Kim J, Park S, Kim JH, Kim SW, Kang WC, Kim SJ. A case of shoshin beriberi presenting as cardiogenic shock with diffuse ST-segment elevation, which dramatically improved after a single dose of thiamine. Cardiovasc J Afr. 2014 Nov 23. 25 (6):e1-5. [Medline].

  36. Isenberg-Grzeda E, Kutner HE, Nicolson SE. Wernicke-Korsakoff-syndrome: under-recognized and under-treated. Psychosomatics. 2012 Nov-Dec. 53(6):507-16. [Medline].

  37. Caine D, Halliday GM, Kril JJ, Harper CG. Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. J Neurol Neurosurg Psychiatry. 1997 Jan. 62(1):51-60. [Medline]. [Full Text].

  38. Duca J, Lum CJ, Lo AM. Elevated Lactate Secondary to Gastrointestinal Beriberi. J Gen Intern Med. 2015 Apr 16. [Medline].

  39. Giacalone M, Martinelli R, Abramo A, Rubino A, Pavoni V, Iacconi P, et al. Rapid reversal of severe lactic acidosis after thiamine administration in critically ill adults: a report of 3 cases. Nutr Clin Pract. 2015 Feb. 30 (1):104-10. [Medline].

  40. Dingwall KM, Delima JF, Gent D, Batey RG. Hypomagnesaemia and its potential impact on thiamine utilisation in patients with alcohol misuse at the Alice Springs Hospital. Drug Alcohol Rev. 2015 May. 34 (3):323-8. [Medline].

  41. Maschke M, Weber J, Bonnet U, et al. Vermal atrophy of alcoholics correlate with serum thiamine levels but not with dentate iron concentrations as estimated by MRI. J Neurol. 2005 Jun. 252(6):704-11. [Medline].

  42. Antunez E, Estruch R, Cardenal C, Nicolas JM, Fernandez-Sola J, Urbano-Marquez A. Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. AJR Am J Roentgenol. 1998 Oct. 171(4):1131-7. [Medline].

  43. Manzo G, De Gennaro A, Cozzolino A, Serino A, Fenza G, Manto A. MR imaging findings in alcoholic and nonalcoholic acute Wernicke's encephalopathy: a review. Biomed Res Int. 2014. 2014:503596. [Medline]. [Full Text].

  44. Charness ME, DeLaPaz RL. Mamillary body atrophy in Wernicke's encephalopathy: antemortem identification using magnetic resonance imaging. Ann Neurol. 1987 Nov. 22(5):595-600. [Medline].

  45. Thomson AD, Cook CC, Touquet R, Henry JA. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department. Alcohol Alcohol. 2002 Nov-Dec. 37(6):513-21. [Medline].

  46. Isenberg-Grzeda E, Hsu AJ, Hatzoglou V, Nelso C, Breitbart W. Palliative treatment of thiamine-related encephalopathy (Wernicke's encephalopathy) in cancer: A case series and review of the literature. Palliat Support Care. 2014 Oct 23. 1-9. [Medline].

  47. Weber W, Kewitz H. Determination of thiamine in human plasma and its pharmacokinetics. Eur J Clin Pharmacol. 1985. 28(2):213-9. [Medline].

  48. Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol Alcohol Suppl. 2000 May-Jun. 35(1):2-7. [Medline].

  49. Morrison AB, Campbell JA. Vitamin absorption studies. I. Factors influencing the excretion of oral test doses of thiamine and riboflavin by human subjects. J Nutr. 1960 Dec. 72:435-40. [Medline].

  50. DeWardener HE, Lennox B. Cerebral beriberi (Wernicke's encephalopathy); review of 52 cases in a Singapore prisoner-of-war hospital. Lancet. 1947 Jan 4. 1(6436):11-7. [Medline].

  51. Smithline HA, Donnino M, Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clin Pharmacol. 2012 Feb 4. 12:4. [Medline]. [Full Text].

  52. Wrenn KD, Slovis CM. Is intravenous thiamine safe?. Am J Emerg Med. 1992 Mar. 10(2):165. [Medline].

  53. Traviesa DC. Magnesium deficiency: a possible cause of thiamine refractoriness in Wernicke-Korsakoff encephalopathy. J Neurol Neurosurg Psychiatry. 1974 Aug. 37(8):959-62. [Medline]. [Full Text].

  54. Hack JB, Hoffman RS. Thiamine before glucose to prevent Wernicke encephalopathy: examining the conventional wisdom. JAMA. 1998 Feb 25. 279(8):583-4. [Medline].

  55. Harper CG, Sheedy DL, Lara AI, Garrick TM, Hilton JM, Raisanen J. Prevalence of Wernicke-Korsakoff syndrome in Australia: has thiamine fortification made a difference?. Med J Aust. 1998 Jun 1. 168(11):542-5. [Medline]. [Full Text].

  56. Behura SS, Swain SP. Neuropsychological functioning in Wernicke's encephalopathy. Ind Psychiatry J. 2015 Jan-Jun. 24 (1):99-103. [Medline].

  57. Oudman E, Nijboer TC, Postma A, Wijnia JW, Van der Stigchel S. Procedural Learning and Memory Rehabilitation in Korsakoff's Syndrome - a Review of the Literature. Neuropsychol Rev. 2015 Jun. 25 (2):134-48. [Medline].

  58. Galvin R, Bråthen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010 Dec. 17(12):1408-18. [Medline].

  59. Caso F, Fiorino A, Falautano M, et al. Treatment of Wernicke's encephalopathy with high dose of thiamine in a patient with pyloric sub-stenosis: description of a case. Neurol Sci. 2010 Dec. 31(6):859-61. [Medline].

  60. Kishimoto Y, Ikeda K, Murata K, Kawabe K, Hirayama T, Iwasaki Y. Rapid development of central pontine myelinolysis after recovery from Wernicke encephalopathy: a non-alcoholic case without hyponatremia. Intern Med. 2012. 51(12):1599-603. [Medline].

  61. Cochrane M, Cochrane A, Jauhar P, Ashton E. Acetylcholinesterase inhibitors for the treatment of Wernicke-Korsakoff syndrome--three further cases show response to donepezil. Alcohol Alcohol. 2005 Mar-Apr. 40(2):151-4. [Medline].

  62. Rustembegovic A, Kundurovic Z, Sapcanin A, Sofic E. A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome. Med Arh. 2003. 57(3):149-50. [Medline].

  63. Luykx HJ, Dorresteijn LD, Haffmans PM, Bonebakker A, Kerkmeer M, Hendriks VM. Rivastigmine in Wernicke-Korsakoff's syndrome: five patients with rivastigmine showed no more improvement than five patients without rivastigmine. Alcohol Alcohol. 2008 Jan-Feb. 43(1):70-2. [Medline].

  64. Luo J. Lithium-mediated protection against ethanol neurotoxicity. Front Neurosci. 2010 Jun 28. 4:41. [Medline]. [Full Text].

  65. Chen G, Luo J. Anthocyanins: are they beneficial in treating ethanol neurotoxicity?. Neurotox Res. 2010 Jan. 17(1):91-101. [Medline].

  66. Scalzo SJ, Bowden SC, Ambrose ML, Whelan G, Cook MJ. Wernicke-Korsakoff syndrome not related to alcohol use: a systematic review. J Neurol Neurosurg Psychiatry. 2015 Jan 14. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.